A recent study based on human brain tissues have confirmed that in AD patients receiving either active (AN1792) or passive (Lecanemab) immunotherapy, microglia mediate Aβ clearance through the triggering receptor expressed on myeloid cells 2 (TREM2)-apolipoprotein E (APOE) signaling axis. The gene discussed is APOE; the disease is Alzheimer disease.